SAVE THE DATE: Wilson Therapeutics to Host Capital Markets Day in Stockholm on 21 March 2018
Wilson Therapeutics (publ) will host a Capital Markets Day in Stockholm on Wednesday, 21 March 2018 for investors, analysts and media. Members of the senior management team will be joined by Frederick K. Askari MD, PhD, Associate Professor and Director of the Wilson Disease program at the University of Michigan, who will share his expert clinical insight on Wilson Disease and perspectives on WTX101 (bis-choline tetrathiomolybdate), a first-in-class copper-protein-binding agent with a unique mechanism of action under investigation by Wilson Therapeutics as a novel therapy for Wilson Disease.
Registration will be from 1:30PM CET and presentations will commence at 1:45PM CET / 7:45AM ET.
The event will be in English and will be webcast. A replay will be made available shortly after the event. Further details will follow in the coming weeks.
To attend please RSVP to Lauren Williams (email@example.com).
About WTX101 (bis-choline tetrathiomolybdate)
WTX101 (bis-choline tetrathiomolybdate) is a first-in-class copper-protein-binding agent with a unique mechanism of action, under investigation as a novel therapy for Wilson Disease. In contrast to current treatments, WTX101 provides an alternative copper-protein binding mechanism by forming a tripartite complex with copper and albumin. WTX101 thereby detoxifies excess copper in both liver and blood, and promotes copper clearance through biliary excretion (the body’s natural route of elimination).
A Phase 2 study evaluating the efficacy and safety of WTX101 in patients with Wilson Disease has successfully been completed. In addition, the active moiety of WTX101, tetrathiomolybdate, has been tested in several previous clinical studies in Wilson Disease patients. The data from these studies suggest that WTX101 can reduce and control free copper levels and improve symptoms and associated disabilities. The data also suggest that WTX101 is generally well tolerated with a low risk of drug-induced neurological worsening. The tolerability profile and the expected once-daily dosing regimen have the potential to improve compliance in Wilson Disease patients, leading to fewer treatment failures and ultimately improved outcomes. WTX101 has received Fast Track designation in the US and orphan drug designation for the treatment of Wilson Disease in the US and EU.
In addition, WTX101 has shown potential as a treatment for several other medical conditions including Amyotrophic Lateral Sclerosis (ALS). WTX101 has received US orphan drug designation for the treatment of ALS.
About Wilson Disease
Copper is an essential trace element that plays a critical role in key physiological cellular processes. Due to its toxic potential, copper is normally tightly bound to copper-carrying proteins inside the liver, and excess copper is eliminated from the body via biliary excretion. Wilson Disease is a rare genetic disorder of impaired copper transport and excretion, caused by loss of function of the ATP7B copper-binding protein. This leads to copper overload in the liver, release of free copper into the blood, and damaging accumulation of copper in the brain and other organs. Untreated Wilson Disease inevitably leads to various combinations and severity of hepatic, neurologic and psychiatric symptoms, and is ultimately fatal.
Wilson Disease affects approximately one in every 30,000 people worldwide, corresponding to a prevalence of approximately 10,000 patients in the US and 15,000 patients in the EU. The therapies currently being used in Wilson Disease were introduced in the 1950s and 60s. Since then, no new treatment options have been developed and considerable unmet medical needs still exist.
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
For further information please contact:
Lauren Williams, Head of Investor Relations, Wilson Therapeutics AB
|+44 7958 669 896
Wilson Therapeutics AB (publ)
Corp. Reg. No.556893-0357
SE-111 43 Stockholm
The information was submitted for publication, through the agency of the contact person set out above, at 07.00 CET on 19 February, 2018.